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AbstrAct
ObjeCtives
To assess the effectiveness and safety of 
prostaglandins used for labour induction.
Design
Systematic review with Bayesian network meta-
analysis
Data sOurCes
The Cochrane Pregnancy and Childbirth Group’s 
Database of Trials (which incorporates the results of a 
broad generic search for all pregnancy and postpartum 
trials). Sources included are CENTRAL, Medline, 
Embase, NHS Economic Evaluation Database, CINAHL, 
relevant journals, conference proceedings, and 
registries of ongoing trials.
eligibility Criteria fOr seleCting stuDies
 Randomised clinical trials of prostaglandin or 
prostaglandin analogues used for third trimester 
cervical ripening or labour induction versus placebo or 
no treatment, alternative prostaglandin dose or 
administration, or a different type of prostaglandin. We 
included studies recruiting women with a viable fetus, 
but had no other restrictions relating to indication for 
labour induction or language of publication. Outcomes 
assessed were serious neonatal morbidity (trialist 
defined) or perinatal death; serious maternal 
morbidity (trialist defined) or death; vaginal delivery 
not achieved within 24 hours, caesarean section, and 
uterine hyperstimulation with fetal heart rate changes.
results
280 randomised clinical trials were included (48 068 
women) in the review. Maternal and neonatal mortality 
and serious morbidity were rarely reported and are 
summarized narratively. Unresolved inconsistency was 
observed for the hyperstimulation outcome. Relative 
to placebo, the odds of failing to achieve a vaginal 
delivery were lowest for vaginal misoprostol (≥ 50 μg) 
(odds ratio 0.06 (95% credible interval 0.02 to 0.12)), 
with a 39% absolute probability of event (95% credible 
interval 1% to 94%). Compared with placebo, odds of 
caesarean section were lowest for titrated oral 
misoprostol solution ( < 50 μg) (odds ratio 0.65 (0.49 
to 0.83)), with an absolute probability of event of 15% 
(3% to 40%).
COnClusiOns
Low dose( < 50 μg) titrated oral misoprostol solution 
had the lowest probability of caesarean section, 
whereas vaginal misprostol (≥50 μg) had the highest 
probability of achieving a vaginal delivery within 24 
hours. These findings have important implications for 
a series of current national and international 
guidelines for induction of labour and future research 
in this area.
systematiC review registratiOn
PROSPERO 2013:CRD42013005116
Introduction
Labour inductions have increased steadily over the past 
two decades, with overall rates in many countries now 
exceeding 20% of all births.1 2 Many different methods 
have been used, but prostaglandins remain a preferred 
method for cervical ripening and labour induction.1 3 4 
Although various prostaglandins have been tested in 
randomised trials, current recommendations have not 
been based on a quantitative overview of the accumu-
lated evidence of their effectiveness and safety. 
 Published meta-analyses have focused on pairwise 
“head to head” comparisons,5–7 but clinicians, women, 
and policy makers tend to make informal indirect com-
parisons between different methods. Such an informal 
approach may lead to incorrect and incoherent conclu-
sions, and there is, therefore, a need to synthesize evi-
dence in a coherent manner.8
Network meta-analysis (also known as multiple treat-
ment meta-analysis or mixed-treatment comparisons) 
allows a formal solution to this issue, preserving 
the  randomized nature of the evidence. A network 
meta-analysis is the simultaneous comparison of multi-
ple competing treatments in a single statistical model 
and is increasingly used in comparative effectiveness 
research.9 The methodology has been available for 
some time10 11 and is internationally recognized by 
health technology assessment organizations12 13 and the 
Cochrane Collaboration.14 Network meta-analysis has 
been applied across clinical areas as diverse as obstet-
rics,15 cardiology,16 psychiatry,17 18 rheumatology,19 and 
surgery20 among others. By exploiting all the available 
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WhAt Is AlreAdy knoWn on thIs topIc
Labour inductions have increased steadily worldwide, with overall rates in many 
countries now exceeding 20% of all births
Many methods have been tested, but prostaglandins remain a preferred method for 
cervical ripening and labour induction
Informal indirect comparisons between different protocols for labour induction may 
lead to incorrect conclusions, and there is therefore a need to synthesize relevant 
evidence in a coherent manner
WhAt thIs study Adds
This network meta-analysis finds that misoprostol may be the best prostaglandin 
for labour induction
Titrated low dose oral solution seems to be the safest in terms of risk of caesarean 
section, while vaginal misoprostol tablets (≥ 50 μg) are the most effective in 
achieving vaginal delivery within 24 hours of induction
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evidence, both direct and indirect, a network meta-anal-
ysis produces estimates of the relative effects of each 
treatment compared with all others in the network, 
even if not all treatments have been directly compared 
with each other. It is then possible to calculate the prob-
ability of one treatment being the best for a specific out-
come; in this way different treatment options can be 
ranked from best to worst for each outcome. 
In this paper we present a network meta-analysis to 
quantify the effects and safety of different prostaglan-
dins used for labour induction. Originally conceived as 
a standalone investigation, it is now also part of a larger 
project looking at all methods for labour induction 
(PROSPERO 2013:CRD42013005116).
Methods
search strategy and selection criteria
To identify potentially eligible trials, we searched the 
Cochrane Pregnancy and Childbirth Group’s Database 
of Trials (which incorporates the results of a broad 
generic search for all pregnancy and postpartum trials). 
Sources searched were CENTRAL, Medline, Embase, 
NHS Economic Evaluation Database, CINAHL, relevant 
journals, conference proceedings, and registries of 
ongoing trials. The full text of every relevant trial report 
was obtained and assigned to a topic depending on the 
intervention before adding to the database. This 
approach leads to a more specific search. We then 
screened all reports assigned to the “induction of 
labour” topic. The detailed search strategy, along with 
references for all reports identified by the search, are in 
appendices 1–3. Information relating to the characteris-
tics of the included studies and different doses and reg-
imens used are outlined in appendices 4 and 5. The 
latest search was completed in March 2014.
We included all randomised clinical trials comparing 
a prostaglandin or prostaglandin analogue used for 
third trimester cervical ripening or labour induction 
with placebo or no treatment, with the same prosta-
glandin administered by a different route or dose, or 
with a different type of prostaglandin. We included only 
studies recruiting women with a viable fetus but had no 
other restrictions relating to indication for labour 
induction, language, or date of publication.
We included 12 different types of prostaglandin or 
prostaglandin analogue: vaginal prostaglandin E2 as 
tablets, gel, pessary, or sustained release pessary; intra-
cervical prostaglandin E2; prostaglandin F2α gel; vagi-
nal misoprostol tablet (dose < 50 μg or ≥ 50 μg) or 
sustained release pessary; oral misoprostol tablet 
(dose  < 50 μg or ≥ 50 μg); and oral misoprostol solution 
(< 50 μg). Intravenous prostaglandins, oral prostaglan-
din E2, and buccal prostaglandin E2 were excluded since 
these routes of administration are rarely used in clinical 
practice.
Each preparation was examined separately as differ-
ent routes of administration and doses may be associ-
ated with differential effects. Trials were eligible for 
inclusion if they compared two or more of these active 
agents or were compared an active agent with placebo 
or no treatment (fig 1). Treatment arms were categorized 
according to the initial randomized allocation, although 
subsequent clinical management may have included 
further doses or an alternative treatment.
Data extraction and assessment of risk of bias
Five reviewers extracted data from the trial reports 
using a specifically designed form capturing informa-
tion on study design, trial setting, patient characteris-
tics, prostaglandin type and dose, and outcomes. All 
reports were read by two reviewers, and disagreement 
was resolved by joint review of the manuscript to reach 
consensus. Our analysis was restricted to five key out-
comes in terms of effectiveness and safety, identified 
as  such by the Cochrane Pregnancy and Childbirth 
Group:21 22
•	 Serious neonatal morbidity (trialist defined) or peri-
natal death
•	 Serious maternal morbidity (trialist defined) or death
•	 Vaginal delivery not achieved within 24 hours
•	 Caesarean section (any indication)
•	 Uterine hyperstimulation with fetal heart rate 
changes.
Study quality was assessed using the methods 
described in the Cochrane Handbook.23 For use in a 
pre-specified sensitivity analysis, we assigned a judg-
ment relating to risk of bias (low, high, unclear) based 
on the allocation concealment domain. We based this 
decision on meta-epidemiological evidence regarding 
sources of bias and design of obstetric trials.24
An important assumption underpinning network 
meta-analysis is that there is consistency between the 
direct and indirect evidence; that is, that the direct and 
indirect estimates of relative treatment effect are simi-
lar. Consistency may be undermined if there is an 
imbalance in effect modifiers across treatment compar-
isons. We therefore pre-specified and extracted infor-
mation on potential key effect modifiers—that is, 
gestational age, parity, previous caesarean section, 
Bishop score, and status of amniotic membranes (intact 
or ruptured). We visually assessed whether the effect 
modifiers were similarly distributed across trials, 
through cross-tabulations.
Data synthesis and statistical analysis
A network meta-analysis was conducted to simultane-
ously compare the 12 prostaglandin treatments and 
placebo or no treatment for each outcome. In its sim-
plest form, a network meta-analysis is the combination 
of direct and indirect estimates of relative treatment 
effect in a single analysis. An indirect estimate of the 
relative treatment effect A versus B can be formed by 
comparing direct trials of A versus C with trials of B 
 versus C. A simple approach to combining the indirect 
and direct estimates of A versus B would be to take a 
weighted average, for example using an inverse vari-
ance weighting.25
All analyses were conducted within a Bayesian 
framework using OpenBUGS.26 Where direct data were 
available, pairwise meta-analyses were also per-
formed and compared with the network meta-analysis 
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treatment effect estimates to informally assess agree-
ment. Studies with 0 or 100% events in all arms were 
excluded from the analysis because these studies pro-
vide no evidence on relative effects.27 For studies with 
a 0 or 100% events in one arm only, we planned to 
analyze the data without continuity corrections where 
computationally possible. To avoid double counting of 
events, multi-arm trials were analysed in their original 
form without the need to combine treatment arms.
Both fixed and random effects models (accounting 
for the correlations induced between trial-specific 
effects in multi-arm trials) were considered on the basis 
of model fit. Goodness of fit was measured using the 
posterior mean of the residual deviance, the degree of 
between-study heterogeneity, and the deviance infor-
mation criterion. In a well fitting model the posterior 
mean residual deviance should be close to the number 
of data points.28 29 Heterogeneity was reported as the 
posterior median between-trial standard deviation (τ) 
with its 95% credible interval. Differences of ≥ 5 points 
for deviance information criterion were considered 
meaningful.28
Consistency between the different sources of evi-
dence was explored statistically by comparing the fit of 
a model assuming consistency with a model which 
allowed for inconsistency.30 If the inconsistency model 
had the smallest posterior mean residual deviance, het-
erogeneity, or deviance information criterion value then 
this indicates potential inconsistency in the data. 
Where model fit was indicative of inconsistency, we 
firstly planned to restrict analysis to those trials with 
adequate allocation concealment. If this did not resolve 
apparent inconsistency we planned further subgroup 
analyses using potential treatment effect modifiers 
identified as being unevenly distributed across the 
treatments. The impact of removing placebo and 
no-treatment nodes from the network was also exam-
ined in sensitivity analyses, because of the possibility 
that such trials may have included lower risk popula-
tions than head-to-head comparisons of active treat-
ments.
Full details of priors and convergence checks are 
given in appendix 7, but they are briefly summarized 
here. Vague prior distributions were specified for treat-
ment effect and heterogeneity parameters. Convergence 
was assessed using the Brooks-Gelman-Rubin diagnos-
tic plots33 34 and was satisfactory by 90 000 simulations 
for all outcomes. A further simulation sample of at least 
180 000 iterations post-convergence was obtained on 
which all reported results were based.
Relative treatment effects are reported as posterior 
median odds ratios and 95% credible intervals. We cal-
culated the probability of each treatment being first, 
second, third, etc, most effective for each outcome. As 
this metric can be unstable, the posterior median of the 
ranking of each treatment (and 95% credible intervals) 
are also reported, with the convention that the lower 
the rank the better the treatment. The absolute proba-
bility of an event on each treatment was also calculated 
by applying the log odds ratios to the log odds esti-
mated from a synthesis of reference treatment (placebo) 
arms.27 We used this to inform the calculation of the 
number needed to treat to harm (all events considered 
here are undesirable). For the interested reader, poste-
rior median risk ratios are also reported in appendix 6 
(table 16).
results
The search identified 540 studies (708 reports) poten-
tially eligible for inclusion in the review. Of these, 260 
studies were excluded (see fig 1 for reasons for exclu-
sion). We included 280 studies in the systematic review, 
and data were available for at least one of our outcomes 
for 48 068 women. The data used in the analyses are 
reported in appendix 6 (tables 10–14).
The complete comparison networks—including 280 
randomised controlled trials of prostaglandins exam-
ining 12 different regimens, no treatment, and pla-
cebo—are presented in figure 2 for failure to achieve 
vaginal delivery in 24 hours, caesarean section, uter-
ine hyperstimulation, serious neonatal morbidity or 
perinatal death, and serious maternal morbidity or 
death.35
vaginal delivery not achieved within 24-hours
After the exclusion of trials with zero events in all arms, 
94 trials were available for network analysis. There were 
no trials remaining that compared prostaglandin F2. 
Meaningful differences were observed in posterior 
mean residual deviance and deviance information 
Studies identied through searching Cochrane Pregnany
and Childbirth Group database of trials (n=540; 708 reports)
No of arms relating to dierent treatments (n=574):
  No treatment (n=31)
  Placebo (n=61)
  Vaginal prostaglandin E2 tablet (n=32)
  Vaginal prostaglandin E2 gel (n=74)
  Vaginal prostaglandin E2 pessary (slow release) (n=35)
  Prostaglandin F2 gel (n=5)
  Intracervical prostaglandin E2 (n=101)
  Vaginal prostaglandin E2 pessary (normal release) (n=19)
  Vaginal misoprostol (dose <50 μg) (n=55)
  Vaginal misoprostol (dose ≥50 μg) (n=92)
  Oral misoprostol (dose <50 μg) (n=3)
  Oral misoprostol (dose ≥50 μg) (n=55)
  Low dose misoprostol solution (n=9)
  Sustained release misoprostol (n=2)
This includes 267 two-arm trials, 12 three-arm trials, and 1
four-arm trial
Excluded from network meta-analysis (n=195):
  Caesarean section analysis (n=11):
    Did not report outcome (n=8)
    Had 0% or 100% rate event on each arm (n=3)
  Vaginal delivery analysis (n=187):
    Did not report outcome (n=186)
    Had 100% event rate on each arm (n=1)
Excluded from systematic review (n=260; 287 reports):
  Not a randomised controlled trial (n=27)
  No relevant outcome data (n=70)
  Not a relevant comparison (n=114)
  Not a relevant participant group (n=9)
  Methodological issues (n=13)
  Insucient information (n=27)
fig 1 | Prisma diagram of study selection for network 
meta-analysis
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VagPGE2tablet = Vaginal prostaglandin E2 tablet; VagPGE2gel = Vaginal prostaglandin E2 gel; VagPGE2pessarySR = Vaginal prostaglandin E2 pessary (slow release); 
cxPGE2 = Intracervical prostaglandin E2; VagPGE2pessary = Vaginal prostaglandin E2 pessary (normal release); VagPGF gel = Vaginal prostaglandin F2 gel; 
VagMiso<50mcg = Vaginal misoprostol (dose <50 μg); VagMiso>50mcg = Vaginal misoprostol (dose ≥50 μg); OMiso<50mcg = Oral misoprostol tablet (dose <50 μg); 
OMiso>50mcg = Oral misoprostol tablet (dose ≥50 μg); TitrOMiso = Titrated (low dose) oral misoprostol solution; VagMisopessarySR = Vaginal misoprostol pessary 
(slow release)
OMiso>50 mcg
OMiso>50 mcg
OMiso<50 mcg
OMiso<50 mcg
OMiso<50 mcg
No treatment
No treatment
No treatment
No treatment
cxPGE2 cxPGE2
cxPGE2
VagPGE2tablet
VagPGE2tablet
VagPGE2tabletVagPGE2pessarySR VagPGE2pessarySR
VagPGE2pessarySR
VagPGE2pessary
VagPGE2pessary
VagPGE2pessary
VagMisopessarySR
VagMisopessarySRVagMiso>50mcg
VagMiso>50mcg
VagMiso>50mcg
VagMiso>50mcg
VagMiso<50mcg VagMiso<50mcg
VagMiso<50mcg
VagMiso<50mcg
TitrOMiso TitrOMiso
TitrOMiso
Placebo
Vaginal delivery not achieved within 24 hours Caesarean section
Uterine hyperstimulation
Serious maternal morbidity or death
Serious neonatal morbidity or perinatal death
Placebo
Placebo
VagPGE2gel
VagPGE2gel
VagPGE2gel
VagPGF2gel
VagPGF2gel
OMiso>50 mcg
OMiso<50 mcg
No treatment
cxPGE2
cxPGE2
VagPGE2tablet
VagPGE2tablet
VagPGE2pessarySR
VagPGE2pessary
VagMisopessarySR
VagMiso>50mcg
VagMiso<50mcg
TitrOMiso Placebo
VagPGE2gel
fig 2 | networks of eligible comparisons for five outcomes: vaginal delivery not achieved within 24 hours, caesarean section, uterine hyperstimulation, 
serious neonatal morbidity or perinatal death, and serious maternal morbidity or death. the width of the lines is proportional to the number of trials 
comparing each pair of treatments, and the size of each node is proportional to the number of randomised participants (sample size)
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 criterion values, suggesting that, for the full network, 
the inconsistency model is preferred over the consis-
tency model (appendix 6, table 7). To explore the source 
of the observed inconsistency, we conducted a pre-spec-
ified sensitivity analysis examining the effect of remov-
ing trials at high risk of bias from the network. The 
random effects model, excluding these trials, provided 
an adequate fit to the data (appendix 6, table 7), and 
reported results are based on this model, with 64 trials 
(Table 1, and fig 3).
Despite the observation of high between-trials het-
erogeneity (τ = 0.47 (95% credible interval 0.34 to 0.63)) 
(relative to the size of the treatment effect estimates as 
measured on the log odds scale), there was strong 
 evidence that all prostaglandins increased the odds of 
achieving a vaginal birth within 24 hours when com-
pared with placebo (Table 1). When active treatments 
were compared, 14 out of 55 comparisons reached con-
ventional level of statistical significance (fig 3). The 
absolute probabilities of failing to achieve a vaginal 
birth within 24 hours are shown in table 1, alongside the 
odds ratios relative to placebo. We note that the abso-
lute probability of an event for vaginal misoprostol tab-
let ≥ 50 μg was 39% (95% credible interval 1% to 94%), 
closely followed by that for titrated (low dose) oral 
misoprostol solution (41% probability (2% to 95%)).
Figure 4 shows the distribution of the rankings for 
each of the 12 prostaglandin treatments. The x axis 
reports each of the possible 12 ranks, where position 1 
means the treatment is ranked the highest and position 
12 the lowest. The y axis shows the probability with 
which each treatment has been ranked at each of the 12 
possible positions and therefore fully encapsulates the 
uncertainty in the treatment rankings. For example, 
consider vaginal prostaglandin E2 tablet in the top 
 left-hand corner of the figure. For the outcome achiev-
ing vaginal delivery within 24 hours of induction, the 
probability of vaginal prostaglandin E2 tablet being 
ranked first is 5%, the probability of being ranked sec-
ond is around 10%, peaking at a 15% probability of 
being ranked sixth. We can conclude from figure 4 that 
there is considerable uncertainty in the estimation of 
any rank for vaginal prostaglandin E2 tablet. Note that 
this uncertainty is also reflected in the credible interval 
around the median rank, which spans from 1st to 9th 
“best” treatment for this outcome.
The best treatment for achieving a vaginal birth 
within 24 hours was vaginal misoprostol tablet ≥ 50 μg, 
with a probability of being best of 53%. The probability 
of being ranked in the top three treatments was 97% for 
vaginal misoprostol tablet ≥ 50 μg and 73% for titrated 
(low dose) oral misoprostol solution. The remaining 
treatments all rated lower than a 40% probability of 
being in the top three treatments. The probability of 
being ranked in the bottom three (that is, poorest in 
terms of achieving a vaginal birth within 24 hours) was 
92% for vaginal prostaglandin E2 pessary (normal 
release), 80% for oral misoprostol  < 50 μg, and 67% for 
intracervical prostaglandin E2.
Caesarean section
After the exclusion of trials with zero or 100% events in 
all arms, 269 trials were available for inclusion in both 
the pairwise and network meta-analyses (fig 2). The 
95% credible intervals from the direct and network 
meta-analysis random effects analyses were overlap-
ping. However, for comparability with the results for the 
vaginal delivery outcome, the results we report here are 
those from the random effects sensitivity analysis, hav-
ing removed trials at high risk of bias (160 trials 
table 1 | results from direct, pairwise meta-analysis (where possible) and network meta-analysis for treatments’ failure 
to achieve vaginal delivery within 24 hours relative to the reference treatment, placebo
treatment comparison
Direct 
comparison network meta-analysis
Odds ratio 
(95% Cri)*
Odds ratio 
(95% Cri)* nnt (95% Cri)†
absolute 
probability 
(95% Cri)
Placebo Reference Reference Reference 0.81 (0.23 to 1.00)
No treatment — 0.32 (0.09 to 1.14) 7 (−49 to 285) 0.66 (0.07 to 0.99)
Vaginal prostaglandin E2 (tablet) — 0.08 (0.03 to 0.20) 3 (2 to 31) 0.45 (0.02 to 0.96)
Vaginal prostaglandin E2 (gel) — 0.08 (0.03 to 0.17) 2 (2 to 27) 0.44 (0.02 to 0.96)
Vaginal prostaglandin E2 pessary (slow release) — 0.10 (0.04 to 0.24) 3 (2 to 37) 0.48 (0.03 to 0.97)
Prostaglandin F2 gel Not in network Not in network Not in network Not in network
Intracervical prostaglandin E2 0.09 (0.03 to 0.24) 0.12 (0.06 to 0.26) 3 (2 to 46) 0.52 (0.03 to 0.97)
Vaginal prostaglandin E2 pessary (normal release) 0.46 (0.07 to 3.09) 0.19 (0.07 to 0.52) 5 (2 to 92) 0.59 (0.05 to 0.98)
Vaginal misoprostol (< 50 μg) — 0.07 (0.03 to 0.16) 2 (2 to 26) 0.43 (0.02 to 0.96)
Vaginal misoprostol (≥ 50 μg) — 0.06 (0.02 to 0.12) 2 (1 to 20) 0.39 (0.01 to 0.94)
Oral misoprostol tablet (< 50 μg) — 0.16 (0.05 to 0.48) 4 (2 to 77) 0.56 (0.04 to 0.98)
Oral misoprostol tablet (≥ 50 μg) 0.10 (0.03 to 0.31) 0.08 (0.04 to 0.18) 3 (2 to 30) 0.46 (0.02 to 0.96)
Titrated oral misoprostol solution (< 50 μg) — 0.06 (0.03 to 0.15) 2 (1 to 23) 0.41 (0.02 to 0.95)
Misoprostol vaginal pessary sustained release — 0.09 (0.03 to 0.35) 3 (1 to 43) 0.47 (0.02 to 0.97)
95% CrI = 95% credible interval. NNT = number needed to treat.
*An odds ratio > 1 favours placebo (that is, fewer events occur with placebo than with active treatment), whereas an odds ratio  < 1 favours active 
treatment (fewer undesirable events occur with active treatment). Empty cells indicate that no direct evidence was available for that comparison. 
†NNTs were calculated based on the absolute odds of an event on the reference treatment. Positive NNTs are interpreted as the number of women 
needed to be treated to prevent one failure to achieve vaginal delivery within 24 hours of induction. Negative NNTs suggest that the treatment is less 
effective than placebo at preventing a failed vaginal delivery within 24 hours.
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Vaginal prostaglandin E2 tablet v
  Vaginal prostaglandin E2 gel
  Vaginal prostaglandin E2 pessary (slow release)
  Intracervical prostaglandin E2
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal prostaglandin E2 (gel) v
  Vaginal prostaglandin E2 pessary  (slow release)
  Intracervical prostaglandin E2
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal prostaglandin E2 pessary  (slow release) v
  Intracervical prostaglandin E2
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Intracervical prostaglandin E2 v
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal prostaglandin E2 pessary (normal release) v
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal misoprostol (dose <50 μg) v
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal misoprostol (dose ≥50 μg) v
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Oral misoprostol tablet (dose <50 μg) v
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Oral misoprostol tablet (dose ≥50 μg) v
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Titrated (low dose) oral misoprostol solution v
  Vaginal misoprostol pessary (sustained release)
0.93 (0.52 to 1.67)
1.23 (0.62 to 2.43)
1.53 (0.85 to 2.74)
2.33 (0.93 to 6.08)
0.90 (0.49 to 1.63)
0.68 (0.38 to 1.21)
1.96 (0.75 to 5.07)
1.04 (0.58 to 1.86)
0.77 (0.38 to 1.53)
1.16 (0.35 to 3.83)
1.32 (0.82 to 2.12)
1.64 (1.14 to 2.38)
2.51 (1.12 to 5.79)
0.96 (0.67 to 1.36)
0.73 (0.53 to 1.01)
2.11 (0.95 to 4.65)
1.11 (0.77 to 1.60)
0.82 (0.53 to 1.28)
1.24 (0.42 to 3.69)
1.24 (0.76 to 2.05)
1.90 (0.80 to 4.67)
0.73 (0.45 to 1.16)
0.55 (0.36 to 0.86)
1.59 (0.66 to 3.88)
0.84 (0.51 to 1.39)
0.62 (0.36 to 1.08)
0.94 (0.36 to 2.50)
1.53 (0.74 to 3.23)
0.59 (0.40 to 0.84)
0.45 (0.31 to 0.63)
1.28 (0.55 to 2.96)
0.68 (0.47 to 0.97)
0.50 (0.30 to 0.83)
0.76 (0.25 to 2.25)
0.38 (0.17 to 0.85)
0.29 (0.13 to 0.65)
0.84 (0.27 to 2.52)
0.44 (0.19 to 0.99)
0.33 (0.13 to 0.79)
0.50 (0.13 to 1.82)
0.76 (0.55 to 1.06)
2.19 (0.99 to 4.83)
1.16 (0.82 to 1.63)
0.86 (0.54 to 1.35)
1.29 (0.44 to 3.83)
2.88 (1.26 to 6.55)
1.52 (1.09 to 2.13)
1.13 (0.69 to 1.82)
1.70 (0.59 to 4.95)
0.53 (0.23 to 1.21)
0.39 (0.16 to 0.93)
0.59 (0.16 to 2.22)
0.74 (0.45 to 1.21)
1.12 (0.38 to 3.37)
1.51 (0.49 to 4.66)
0.1 1 2 5 10
Treatment comparison; control v active treatment Odds ratio
(95% credible interval)
Odds ratio
(95% credible interval)
fig 3 | Odds ratios and 95% credible intervals from network meta-analysis of failure to achieve vaginal delivery within 24 
hours. an odds ratio  > 1 favours control (that is, fewer events occur with control than with active treatment), while an 
odds ratio  < 1 favours the active treatment (fewer undesirable events occurred with the active treatment)
RESEARCH
7the bmj | BMJ 2015;350:g217 | doi: 10.1136/bmj.h217
included). We note that the results are not materially 
different between the full network (269 trials) and the 
sensitivity analysis network (160 trials).
Table 2 reports the posterior median odds ratios (95% 
credible intervals) for each treatment relative to placebo 
(the full results are reported in appendix 6, table 5). We 
note that, for all but vaginal prostaglandin E2 tablet ver-
sus placebo (Table 2), the direct and network meta-anal-
ysis results are similar. However, this is consistent with 
chance (from 49 statistical tests we might expect 2.5 to 
be significant by chance), and we did not observe any 
meaningful difference in residual deviance or deviance 
information criterion values between the inconsistency 
and consistency models for caesarean section (appendix 
6, table 8). Relative to the size of the treatment effect esti-
mates, between-trial heterogeneity was observed for this 
outcome (τ = 0.09 (95% credible interval 0.003 to 0.22)). 
When active treatments were compared, six out of 66 
comparisons reached the conventional level of statisti-
cal significance (fig 5). With placebo used as the refer-
ence (Table 2), five active treatment regimens resulted in 
significant reduction in caesarean section, namely vagi-
nal prostaglandin E2 (gel), vaginal misoprostol tab-
let < 50 μg, vaginal misoprostol tablet ≥ 50 μg, oral 
misoprostol tablet ≥ 50 μg, and titrated (low dose) oral 
misoprostol solution.
The safest treatment in terms of caesarean section 
risk was titrated (low dose) oral misoprostol solution, 
with a 70% probability of being the best and with the 
best (lowest) median ranking (fig 4). The absolute prob-
ability of an event for titrated oral misoprostol was 15% 
(95% credible interval 3% to 40%). The probability of 
being ranked in the top three treatments was 92% for 
titrated (low dose) oral misoprostol solution and 66% 
Ranking
Vaginal prostaglandin E2 (tablet)
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0.4
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0.8
Vaginal delivery 5 (1 to 9)
Caesarean section 9 (3 to 12)
Ranking
Vaginal prostaglandin E2 (gel)
1 2 3 4 5 6 7 8 9 10 11 12
Vaginal delivery 4 (2 to 8)
Caesarean section 6 (3 to 9)
Ranking
Vaginal prostaglandin E2 pessary (slow release)
1 2 3 4 5 6 7 8 9 10 11 12
Vaginal delivery 7 (3 to 10)
Caesarean section 8 (2 to 11)
0.2
Prostaglandin F2 gel
Pr
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ty
0
0.4
0.6
0.8
Caesarean section 9 (1 to 12)
Intracervical prostaglandin E2
Vaginal delivery 9 (7 to 10)
    Caesarean section 7 (4 to 10)
Vaginal prostaglandin E2 pessary (normal release)
Vaginal delivery 11 (6 to 11)
    Caesarean section 10 (3 to 12)
0.2
Vaginal misoprostol (dose <50 μg)
Pr
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ili
ty
0
0.4
0.6
0.8
Vaginal delivery 4 (2 to 7)
    Caesarean section 4 (2 to 8)
Vaginal misoprostol (dose ≥50 μg)
Vaginal delivery 1 (1 to 4)
    Caesarean section 3 (1 to 7)
Oral misoprostol tablet (dose <50 μg)
Vaginal delivery 10 (4 to 11)
    Caesarean section 11 (3 to 12)
0.2
Oral misoprostol tablet (dose ≥50 μg)
Pr
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0
0.4
0.6
0.8
Vaginal delivery 6 (3 to 8)
    Caesarean section 3 (1 to 7)
Titrated (low dose) oral misoprostol solution
Vaginal delivery 2 (1 to 7)
    Caesarean section 1 (1 to 5)
Sustained release misoprostol pessary
Vaginal delivery 7 (1 to 11)
    Caesarean section 9 (1 to 12)
0.2
fig 4 | ranking for each of the 12 prostaglandin treatments for vaginal delivery not achieved within 24 hours and caesarean section. ranking indicates the 
probability of being the best treatment, the second best, the third best, etc. for comparability across outcomes, rankings are based on the sensitivity 
analysis having excluded studies at high risk of bias
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for oral misoprostol tablet ≥50 μg. All other treatments 
had a lower probability of being among the top three. 
The probability of being ranked in the bottom three 
(poorest in terms of risk of caesarean section) was 56% 
for vaginal prostaglandin E2 pessary (normal release) 
and 77% for oral misoprostol tablet < 50 μg.
uterine hyperstimulation with fetal heart changes
After the exclusion of trials with zero or 100% events in 
all arms, 129 trials assessed the outcome of uterine 
hyperstimulation. Model fit statistics indicated 
 evidence of inconsistency for this network (appendix 6, 
table 9). A pre-specified sensitivity analysis examining 
the effect of removing trials at high risk of bias from the 
network and subgroup analyses exploring inclusion- 
exclusion criteria for previous caesarean section, mem-
brane status, and gestational length did not explain the 
observed inconsistency. Consequently, we were not able 
to report robust network meta-analysis estimates or 
ranking for this outcome (appendix 6, table 6). The 
results from the direct head-to-head meta-analyses are 
reported in appendix 6, table 6. We note that, of 25 
active versus active treatment comparisons, only two 
achieved conventional statistical significance. Com-
pared with intracervical prostaglandin E2, vaginal miso-
prostol ≥ 50 μg was associated with a fourfold increase 
in the odds of uterine hyperstimulation (odds ratio 3.57 
(95% credible interval 1.66 to 8.06)). Similarly, vaginal 
misoprostol ≥ 50 μg was associated with a near three-
fold increase in the odds of hyperstimulation compared 
with slow release vaginal prostaglandin E2 (odds ratio 
2.73 (1.08 to 7.40))
mortality and severe morbidity
Neonatal and maternal mortality and serious morbidity 
outcomes were too rare or poorly reported to carry out 
meaningful analysis even with a continuity correction 
of 0.5 added to each cell (see appendix 6, tables 10–14). 
Given the lack of universally accepted definitions of 
serious infant or maternal morbidity we planned to 
include any reported by individual trials. However, 
even when defined in such a way, they were rarely 
reported. For this reason, the data included in the anal-
ysis are for perinatal and maternal death only. Fifty one 
of the 280 included trials (18.2%) reported perinatal 
deaths with an incidence of 0.2% (30/14 367). Eighteen 
out of 280 trials (6%) reported a total of four maternal 
deaths.
subgroup and sensitivity analyses
The full details of the subgroup analyses are reported in 
appendix 6 (table 15). Our findings were robust when 
we removed studies with placebo and no-treatment 
arms from the analyses. With regards to median rank-
ing, titrated (low dose) oral misoprostol solution was 
still the highest ranking active treatment for caesarean 
section. For achieving vaginal delivery within 24 hours, 
vaginal misoprostol ≥ 50 μg was still the highest ranked 
treatment, with titrated low does oral misoprostol solu-
tion ranked second (based on median ranks).
For each outcome, we examined the distribution of 
potential effect modifiers by comparing the proportion 
of trials containing each of the pre-specified character-
istics (appendix 6, tables 1–3). For the outcome of cae-
sarean section, previous caesarean section as an 
inclusion-exclusion criterion seemed unevenly distrib-
uted; all trials with a titrated low dose oral misoprostol 
solution arm had excluded women with a previous cae-
sarean section, as did both trials with a sustained 
release misoprostol vaginal pessary arm. In contrast, 
only 31% of trials with an intracervical prostaglandin 
E2 arm (31/99) and only 48% of trials with a vaginal 
table 2 | results from direct, pairwise meta-analysis (where possible) and network meta-analysis for treatments’ risk of 
caesarean section relative to the reference treatment, placebo
treatment comparison
Direct comparison network meta-analysis
Odds ratio 
(95% Cri)*
Odds ratio 
(95% Cri)* nnt (95% Cri)†
absolute 
probability 
(95% Cri)
Placebo Reference Reference Reference 0.21 (0.05 to 0.50)
No treatment — 1.00 (0.74 to 1.32) 24 (−953 to 1092) 0.21 (0.05 to 0.51)
Vaginal prostaglandin E2 (tablet) 0 (0 to 0.69) 0.93 (0.70 to 1.23) 37 (−682 to 722) 0.20 (0.04 to 0.49)
Vaginal prostaglandin E2 (gel) 0.89 (0.68 to 1.18) 0.80 (0.68 to 0.95) 35 (13 to 182) 0.18 (0.04 to 0.45)
Vaginal prostaglandin E2 pessary (slow release) 0.56 (0.25 to 1.19) 0.89 (0.67 to 1.15) 40 (−547 to 621) 0.19 (0.04 to 0.48)
Prostaglandin F2 gel 0.67 (0.24 to 1.89) 0.98 (0.57 to 1.59) 17 (−503 to 491) 0.20 (0.04 to 0.51)
Intracervical prostaglandin E2 0.85 (0.66 to 1.1) 0.86 (0.72 to 1.02) 47 (−167 to 389) 0.19 (0.04 to 0.47)
Vaginal prostaglandin E2 pessary (normal release) 0.82 (0.44 to 1.54) 0.98 (0.70 to 1.35) 25 (−746 to 771) 0.21 (0.05 to 0.50)
Vaginal misoprostol (< 50 μg) 1.09 (0.58 to 2.06) 0.76 (0.62 to 0.92) 28 (11 to 135) 0.17 (0.04 to 0.44)
Vaginal misoprostol (≥ 50 μg) 0.86 (0.14 to 5.57) 0.74 (0.60 to 0.89) 25 (11 to 104) 0.17 (0.04 to 0.43)
Oral misoprostol tablet (< 50 μg) — 1.17 (0.70 to 1.85) −17 (−488 to 450) 0.23 (0.05 to 0.55)
Oral misoprostol tablet (≥ 50 μg) 0.59 (0.36 to 0.95) 0.72 (0.59 to 0.89) 24 (10 to 102) 0.16 (0.03 to 0.43)
Titrated oral misoprostol solution (< 50 μg) — 0.65 (0.49 to 0.83) 18 (8 to 75) 0.15 (0.03 to 0.40)
Misoprostol vaginal pessary sustained release — 0.97 (0.61 to 1.48) 21 (−565 to 615) 0.20 (0.04 to 0.50)
95% CrI = 95% credible interval. NNT = number needed to treat.
*An odds ratio  > 1 favours placebo (that is, fewer events occur with placebo than with active treatment), whereas an odds ratio  < 1 favours active 
treatment (fewer undesirable events occur with active treatment). Empty cells indicate that no direct evidence was available for that comparison. 
†NNTs were calculated based on the absolute odds of an event on the reference treatment. Positive NNTs are interpreted as the number of women 
needed to be treated to prevent one caesarean section. Negative NNTs suggest that the treatment is less effective than placebo at preventing a 
caesarean section.
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Vaginal prostaglandin E2 tablet v
  Vaginal prostaglandin E2 (gel)
  Vaginal prostaglandin E2 pessary  (slow release)
  Prostaglandin F2 gel
  Intracervical prostaglandin E2
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal prostaglandin E2 (gel) v
  Vaginal prostaglandin E2 pessary  (slow release)
  Prostaglandin F2 gel
  Intracervical prostaglandin E2
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal prostaglandin E2 pessary  (slow release) v
  Prostaglandin F2 gel
  Intracervical prostaglandin E2
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Prostaglandin F2 gel v
  Intracervical prostaglandin E2
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Intracervical prostaglandin E2 v
  Vaginal prostaglandin E2 pessary (normal release)
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal prostaglandin E2 pessary (normal release) v
  Vaginal misoprostol (dose <50 μg)
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal misoprostol (dose <50 μg) v
  Vaginal misoprostol (dose ≥50 μg)
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Vaginal misoprostol (dose ≥50 μg) v
  Oral misoprostol tablet (dose <50 μg)
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Oral misoprostol tablet (dose <50 μg) v
  Oral misoprostol tablet (dose ≥50 μg)
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Oral misoprostol tablet (dose ≥50 μg) v
  Titrated (low dose) oral misoprostol solution
  Vaginal misoprostol pessary (sustained release)
Titrated (low dose) oral misoprostol solution v
  Vaginal misoprostol pessary (sustained release)
0.88 (0.68 to 1.12)
0.97 (0.68 to 1.33)
1.07 (0.58 to 1.80)
0.94 (0.71 to 1.21)
1.08 (0.71 to 1.56)
0.83 (0.63 to 1.08)
0.80 (0.62 to 1.02)
1.27 (0.73 to 2.07)
0.79 (0.59 to 1.03)
0.71 (0.51 to 0.96)
1.06 (0.63 to 1.66)
1.10 (0.86 to 1.40)
1.22 (0.72 to 1.96)
1.07 (0.91 to 1.24)
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0.95 (0.81 to 1.10)
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0.90 (0.76 to 1.06)
0.81 (0.65 to 0.99)
1.21 (0.77 to 1.81)
1.13 (0.63 to 1.87)
0.98 (0.75 to 1.26)
1.13 (0.76 to 1.61)
0.87 (0.67 to 1.12)
0.84 (0.66 to 1.06)
1.34 (0.77 to 2.16)
0.83 (0.63 to 1.07)
0.74 (0.54 to 0.99)
1.10 (0.77 to 1.53)
0.93 (0.54 to 1.49)
1.07 (0.58 to 1.78)
0.83 (0.48 to 1.34)
0.80 (0.47 to 1.28)
1.27 (0.60 to 2.35)
0.79 (0.45 to 1.29)
0.70 (0.40 to 1.14)
1.06 (0.52 to 1.91)
1.15 (0.83 to 1.54)
0.89 (0.75 to 1.05)
0.86 (0.73 to 1.01)
1.36 (0.82 to 2.13)
0.85 (0.70 to 1.01)
0.76 (0.59 to 0.96)
1.14 (0.72 to 1.71)
0.79 (0.56 to 1.09)
0.76 (0.55 to 1.04)
1.21 (0.68 to 2.01)
0.75 (0.53 to 1.05)
0.67 (0.46 to 0.95)
1.01 (0.59 to 1.63)
0.97 (0.82 to 1.13)
1.54 (0.93 to 2.38)
0.95 (0.80 to 1.12)
0.85 (0.67 to 1.07)
1.28 (0.91 to 1.92)
1.59 (0.96 to 2.49)
0.99 (0.84 to 1.15)
0.88 (0.69 to 1.11)
1.33 (0.85 to 1.97)
0.66 (0.39 to 1.02)
0.59 (0.34 to 0.93)
0.88 (0.45 to 1.55)
0.90 (0.70 to 1.14)
1.35 (0.85 to 2.04)
1.52 (0.93 to 2.35)
0.4 1 2 4
Treatment comparison; control v active treatment Odds ratio
(95% credible interval)
Odds ratio
(95% credible interval)
fig 5 | Odds ratios and 95% credible intervals from network meta-analysis of caesarean section. an odds ratio  > 1 favours 
control (that is, fewer events occur with control than with active treatment), while an odds ratio  < 1 favours the active 
treatment (fewer undesirable events occurred with the active treatment)
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 prostaglandin E2 pessary (normal release) arm excluded 
women with a previous caesarean section (appendix 6, 
table 2). A similar distribution of characteristics was 
observed for failure to achieve vaginal delivery within 
24 hours (appendix 6, table 1).
It is possible that these differences were partly due to 
poor reporting (that is, inclusion and exclusion criteria 
were not always well reported). Nevertheless, subgroup 
analyses were conducted for both vaginal delivery and 
caesarean section outcomes, in which we removed 
 trials which had randomized women with previous 
 caesarean section (either all or some participants). The 
findings were robust when these trials were removed 
from the analyses, with titrated (low dose) oral miso-
prostol solution still being the highest ranking treat-
ment for the outcome of caesarean section, and vaginal 
misoprostol ≥ 50 μg remaining the highest ranking 
treatment for achieving vaginal delivery within 24 
hours (see appendix 6, table 15). The one noticeable 
change in results was the median rank of oral misopros-
tol tablet < 50 μg, which increased from 11 for the 
 outcome of caesarean section to 4 when trials in which 
some women who had previously had a caesarean 
 section were removed.
discussion
Principal findings
Network meta-analysis provides a unique opportunity 
to rank prostaglandin treatments in a coherent, meth-
odologically robust manner, and allows comparisons to 
be made across outcomes (figs 3–5), to help guide clini-
cians and patients to make informed treatment choices. 
This network meta-analysis showed that misoprostol is 
likely to be superior to dinoprostone (prostaglandin E2) 
for labour induction. On balance, if treatment rankings 
for vaginal delivery within 24 hours and caesarean sec-
tion were informally combined, oral misoprostol solu-
tion  < 50 μg would seem the most highly ranked 
treatment across the two outcomes, followed by high 
dose misoprostol vaginal tablets and then low dose vag-
inal misoprostol tablets. However, the width of the cred-
ible intervals around the posterior median ranks was 
considerable, and so we urge caution in the interpreta-
tion of rankings and the probability that treatments are 
“best.” In particular, we note the uncertainty around 
sustained release vaginal misoprostol: there was insuf-
ficient evidence to draw conclusions about its relative 
safety and efficacy compared with vaginal tablets, 
which have been examined in a larger number of trials 
(and are estimated with greater certainty).
strengths and limitations of the study
We have made a considerable effort to include all rele-
vant randomised controlled trials with no language or 
setting restrictions: 280 studies with data for 48 068 
women were included in the systematic review, which is 
a particular strength of this study. We have started from 
the premise that all 12 treatment regimens would be 
suitable for all included women. This underlying 
assumption of “transitivity” is critically important for 
the network meta-analysis. To evaluate this, we 
extracted the data for six potential treatment modifiers 
(previous caesarean section, parity, status of amniotic 
membranes, Bishop score, gestational age, and single-
ton or multiple pregnancy) and found no clinically 
important differences between the 12 regimens (appen-
dix 6, tables 1–3). We took the view that the trial’s set-
ting was not likely to be a critical treatment modifier 
because in the included trials intrapartum fetal moni-
toring and immediate access to caesarean section were 
available to most women. As this may not be the case in 
low resource settings, the findings from our analysis are 
more likely to be applicable to high resource settings.
In terms of efficacy, we focused on the ability of pros-
taglandins to result in vaginal delivery within 24 hours. 
This definition of efficacy may be seen as controversial 
given that cervical ripening is often regarded as a 
 distinctly different process from induction of labour.1 
This view is reflected by the fact that cervical changes 
measured by the Bishop score are often the main mea-
sure of efficacy in included randomised trials. We argue 
that both women and clinicians view cervical ripening 
and labour induction as a seamless process, with the 
main aim being to achieve safe vaginal birth of a healthy 
baby in the shortest time possible. In this respect, miso-
prostol seems to be superior to other prostaglandins.
We anticipated that serious maternal and neonatal 
adverse events would be rare in cohorts of women 
recruited to randomised trials of labour induction. 
It was, nevertheless, disappointing how infrequently 
mortality and serious morbidity were adequately 
reported. We note that only 51 out of 280 trials reported 
that they had assessed perinatal death, and only 18 
reported assessing maternal death (appendix 6). Where 
these outcomes were reported, they were rare: 30 out of 
51 trials reporting perinatal death and 14 out of 18 trials 
that reported maternal death did not observe events in 
either arm of the trial. Assessment of safety was, there-
fore, limited to caesarean section. All prostaglandins, 
misoprostol in particular, even in low doses, are known 
to cause uterine rupture with possible catastrophic con-
sequences, particularly in women with previous caesar-
ean section.31 The efficacy of both high and low dose 
vaginal misoprostol has to be seen in this context.
In order to form a judgment of which prostaglandin is 
most effective, we could have formally combined the 
outcomes vaginal delivery within 24 hours and caesar-
ean section. However, to do so would assume that each 
outcome is of equal importance. Outcomes are rarely of 
equal importance, particularly when efficacy and safety 
data are combined. A more rigorous approach to obtain 
a single overall summary would be to identify utility 
weights for the different outcomes to provide a weighted 
average. The expected utility gain could then be com-
pared with the expected costs of the treatments in a 
cost-effectiveness analysis. This is an area for further 
work.
We had intended to include uterine hyperstimulation 
in our network meta-analysis. Unfortunately, results 
relating to uterine hyperstimulation were not always 
reported, and, when they were, hyperstimulation was 
defined inconsistently or not all. These issues are likely 
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to have contributed to the difficulties in model fitting 
and statistical inconsistency observed for this outcome. 
In practice, caesarean section and uterine hyperstimu-
lation are clearly related—one would expect that clini-
cally persistent, clinically important uterine 
hyperstimulation will eventually result in caesarean 
section.
Conclusions and implications for practice
The best safety profile of low dose misoprostol solution 
with reasonable efficacy (median rank 2) may have 
important implications for clinical practice. It is note-
worthy that this method is currently not recommended 
by the World Health Organization,32 while low dose 
(25 μg) oral tablets every 2 hours are recommended 
despite the worst overall ranking in our network 
meta-analysis.4 In clinical situations where less fre-
quent vaginal administration of misoprostol may be 
preferable, particularly in settings with intensive moni-
toring facilities, 50 μg vaginal misoprostol tablets may 
be a reasonable treatment of choice. Most of the studies 
in our network meta-analysis used 4 hourly treatment 
regimens, and some opted for less frequent administra-
tion (6 hourly).
Overall, misoprostol may be the best prostaglandin 
for labour induction, as titrated low dose oral solution 
seems to be the safest in terms of caesarean section risk, 
while vaginal misoprostol tablets (≥ 50 μg) are the most 
effective in achieving vaginal delivery within 24 hours 
of induction. These findings have important implica-
tions for national and international guidelines for 
induction of labour and future research in this area.
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